Drug Type Small molecule drug |
Synonyms Alpha-hederin |
Target |
Action inhibitors |
Mechanism SMAD2 inhibitors(Mothers against decapentaplegic homolog 2 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC41H66O12 |
InChIKeyKEOITPILCOILGM-LLJOFIFVSA-N |
CAS Registry27013-91-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hyperlipidemias | China | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Triple Negative Breast Cancer | Preclinical | China | 08 Mar 2025 | |
| Breast Cancer | Preclinical | Sri Lanka | 12 Apr 2024 | |
| Non-Small Cell Lung Cancer | Preclinical | China | 01 Feb 2024 |





